Book Text

1187

REFERENCES

1. Wilson RD, Nichols RJ Jr, Dent TE, et al: Disturbances of the oxidative-phosphorylation mechanism as a possible etiological factor in sudden unexplained hyperthermia occurring during anesthesia. Anesthesiology 27:231, 1966.

2. Ording H: Investigation of malignant hyperthermia susceptibility in Denmark. Dan Med Bull 43:111, 1996.

3. Harrison GG, Issacs H: Malignant hyperthermia: An historical vignette. Anaesthesia 47:54, 1992.

4. Ombrédanne L: De l'influence de l'anesthésique employé dans la ganèse des accidents post-opératoires de pâleur-hyperthermie observés chez les nourrissons. Rev Med Française 10:617, 1929.

5. Denborough MA, Lovell RRH: Anaesthetic deaths in a family. Lancet 2:45, 1960.

6. Kalow W, Britt BA, Terreau ME, et al: Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet 2:89, 1970.

7. Herter M, Wilsdorf G: Die Bedeutung des Schweines für die Fleischversorgung, vol 270. Berlin, Arbeiten der Deutscher Landwirtschaft-Gesellschaft, 1914.

8. Briskey EJ: Etiological status and associated studies of pale, soft, exudative porcine musculature. Adv Food Res 13:89, 1964.

9. Topel DG, Bicknell EJ, Preston KS, et al: Porcine stress syndrome. Mod Vet Pract 49:40, 1968.

10. Hall LW, Woolf N, Bradley JWP, et al: Unusual reaction to suxamethonium chloride. Br Med J 2:1305, 1966.

11. Berman MC, Harrison GG, Bull AB, et al: Changes underlying halothane-induced malignant hyperpyrexia in Landrace pigs. Nature 225:653, 1970.

12. Harrison GG: Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. Br J Anaesth 47:62, 1975.

13. Kolb ME, Horne ML, Martz R: Dantrolene in human malignant hyperthermia: A multicenter study. Anesthesiology 56:254, 1982.

14. Bendixen D, Skovgaard LT, Ording H: Analysis of anaesthesia in patients susceptible to malignant hyperthermia before diagnostic in vitro contracture test. Acta Anaesth Scand 41:480, 1997.

15. Gronert GA, Milde JH: Variations in onset of porcine malignant hyperthermia. Anesth Analg 60:499, 1981.

16. Pollock N, Hodges M, Sendall J: Prolonged malignant hyperthermia in the absence of triggering agents. Anaesth Intensive Care 20:520, 1992.

17. Berchtold MW, Brinkmeier H, Muntener M: Calcium ion in skeletal muscle: Its crucial role for muscle function, plasticity, and disease. Physiol Rev 80:1215, 2000.

18. Kleopa K, Barchi RL: Genetic disorders of neuromuscular ion channels. Muscle Nerve 26:299, 2002

19. Du GG, Sandhu B, Khanna VK, et al: Topology of the Ca²⁺ release channel of skeletal muscle sarcoplasmic reticulum (R_Y R1). Proc Natl Acad Sci 99:16725, 2002.

20. Xiao B, Masumiya H, Jiang D, et al: Isoform-dependent formation of heteromeric Ca²⁺ release channels (ryanodine receptors). J Biol Chem 277:41778, 2002.

21. Grabner M, Dirksen RT, Suda N, et al: The II-III loop of the skeletal muscle dihydropyridine receptor is responsible for the bi-directional coupling with the ryanodine receptor. J Biol Chem 274:21913, 1999.

22. Wilkens CM, Kasielke N, Flucher BE, et al: Excitation-contraction coupling is unaffected by drastic alteration of the sequence surrounding residues L720-L764 of the alpha(1S) II-III loop, Proc Natl Acad Sci U S A 98:5892, 2001.

23. Feng W, Tu J, Yang T, et al: Homer regulates gain of ryanodine receptor type 1 channel complex. J Biol Chem 277:44722, 2002.

24. McWilliams S, Nelson T, Sudo RT, et al: Novel skeletal muscle ryanodine receptor mutation in a large Brazilian family with malignant hyperthermia. Clin Genet 62:80, 2002.

25. Sambuughin N, Sei Y, Gallagher KL, et al: North American malignant hyperthermia population—Screening of the ryanodine receptor gene and identification of novel mutations. Anesthesiology 95:594, 2001.

26. Robinson RL, Brooks C, Brown SL, et al: RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes. Hum Mutation 20:88, 2002.

27. McCarthy TV, Quane KA, Lynch PJ: Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat 15:410, 2000.

28. Lynch PJ, McCarthy T: Molecular aspects of malignant hyperthermia and central core disease. Channelopathies 3:55, 2000.

29. Brown RL, Pollock NA, Couchman KG, et al: A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree. Hum Mol Genet 9:1515, 2000.

30. Monnier N, Krivosic-Horber R, Payen J-F, et al: Presence of two different genetic traits in malignant hyperthermia families: Implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. Anesthesiology 97:1067, 2002.

31. Fletcher JE, Tripolitis L, Hubert M, et al: Genotype and phenotype relationships for mutations in the ryanodine receptor in patients referred for diagnosis of malignant hyperthermia. Br J Anaesth 75:307, 1995.

32. Robinson R, Hopkins P, Carsana A, et al: Several interacting genes influence the malignant hyperthermia genotype. Hum Genet 112:217, 2003.

33. Urwyler A, Deufel T, McCarthy T, et al: Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br J Anaesth 86:283, 2001.

34. Rueffert H, Olthoff D, Deutrich C, et al: Mutation screening in the ryanodine receptor 1 gene (RYR1) in patients susceptible to malignant hyperthermia who show definite IVCT results: Identification of three novel mutations. Acta Anaesth Scand 46:692, 2002.

35. Ryan JF, Lopez JR, Sanchez VB, et al: Myoplasmic calcium changes precede metabolic and clinical signs of porcine malignant hyperthermia. Anesth Analg 79:1007, 1994.

36. Fujii J, Otsu K, Zorzato F, et al: Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 253:448, 1991.

37. O'Brien PJ, Li G: Rapid, simple and sensitive microassay for skeletal muscle homogenates in the functional assessment of the Ca²⁺ -release channel of sarcoplasmic reticulum: Application to diagnosis of susceptibility to malignant hyperthermia. Mol Cell Biochem 167:61, 1997.

38. Owen VJ, Taske NL, Lamb GD: Reduced Mg²⁺ inhibition of Ca²⁺ release in muscle fibers of pigs susceptible to malignant hyperthermia. Am J Physiol 272:C203, 1997.

39. Duke AM, Hopkins PM, Steele DS: Effects of Mg²⁺ and SR luminal Ca²⁺ on caffeine-induced Ca²⁺ release in skeletal muscle from humans susceptible to malignant hyperthermia. J Physiology 544:85, 2002.

40. Yamaguchi N, Igami K, Kasai M: Kinetics of depolarization-induced calcium release from skeletal muscle triads in vitro. J Biochem 121:432, 1997.

41. Paul-Pletzer K, Palnitkar SS, Jimenez LS, et al: The skeletal muscle ryanodine receptor identified as a molecular target of [3H]azidodantrolene by photoaffinity labeling. Biochemistry 40:531, 2001.

42. Paul-Pletzer K, Yamamoto T, Bhat MB, et al: Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor. J Biol Chem 277:34918, 2002.

43. Ikemoto N, Yamamoto T: Postulated role of inter-domain interaction within the ryanodine receptor in Ca²⁺ channel. Trends Cardiovasc Med 10:310, 2000.

44. Yamamoto T, Ikemoto N: Spectroscopic monitoring of local conformational changes during the intramolecular domain-domain interaction of the ryanodine receptor. Biochemistry 41:1492, 2002.

45. Monnier N, Romero NB, Lerale J: Familial and sporadic forms of central core disease are associated with mutations in the C-terminal domain of the skeletal muscle ryanodine receptor. Hum Mol Gen 10:2581, 2001.

46. Gronert GA: Malignant hyperthermia. Anesthesiology 53:395, 1980.

1188

47. Hall GM, Bendall JR, Lucke JN, et al: Porcine malignant hyperthermia. II. Heat production. Br J Anaesth 48:305, 1976.

48. Stadhouders AM, Viering WAL, Verburg MP, et al: In vivo induced malignant hyperthermia in pigs. III. Localization of calcium in skeletal muscle mitochondria by means of electron microscopy and microprobe analysis. Acta Anaesthesiol Scand 28:14, 1984.

49. Saltzman LS, Kates RA, Corke BC, et al: Hyperkalemia and cardiovascular collapse after verapamil and dantrolene administration in swine. Anesth Analg 63:272, 1984.

50. Harrison GG, Wright IG, Morrell DF: The effects of calcium channel blocking drugs on halothane initiation of malignant hyperthermia in MHS swine and on the established syndrome. Anaesth Intensive Care 16:197, 1988.

51. Gallant EM, Foldes FF, Rempel WE, et al: Verapamil is not a therapeutic adjunct to dantrolene in porcine malignant hyperthermia. Anesth Analg 64:601, 1985.

52. Gronert GA, Ahern CP, Milde JH, et al: Effect of CO₂ , calcium, digoxin, and potassium on cardiac and skeletal muscle metabolism in malignant hyperthermia susceptible swine. Anesthesiology 64:24, 1986.

53. Quinlan JG, Iaizzo PA, Gronert GA, et al: Use of dantrolene plus multiple pulses to detect stress-susceptible porcine muscles. J Appl Physiol 60:1313, 1986.

54. Quinlan JG, Wedel DJ, Iaizzo PA: Multiple-pulse stimulation and dantrolene in malignant hyperthermia. Muscle Nerve 13:904, 1990.

55. Hoyer A, Veeser M, Albrecht Y: Repetitive stimulation differentiates distinctly malignant hyperthermia-susceptible (MHS) from non-susceptible (MHN) human muscles in vitro. Anesthesiology 95:A1017, 2001.

56. Bendall JR: The effect of pre-treatment of pigs with curare on the postmortem rate of pH fall and onset of rigor mortis in the musculature. J Sci Food Agric 17:333, 1966.

57. Schmidt GR, Goldspink G, Roberts T, et al: Electromyography and resting membrane potential in longissimus muscle of stress-susceptible and stress-resistant pigs. J Anim Sci 34:379, 1972.

58. Gallant EM, Gronert GA, Taylor SR: Cellular membrane potential and contractile threshold in mammalian skeletal muscle susceptible to malignant hyperthermia. Neurosci Lett 28:181, 1982.

59. Wieland SJ, Gong Q-H, Fletcher JE, et al: Altered sodium current response to intracellular fatty acids in halothane-sensitive skeletal muscle. Am J Physiol 271:C347, 1996.

60. Duthie GG, Arthur JR: Free radicals and calcium homeostasis: Relevance to MH? Free Radic Biol Med 14:435, 1993.

61. Martucci RW, Jessup DA, Gronert GA, et al: Blood gases and catecholamine levels in capture stressed desert bighorn sheep. J Wildl Dis 28:250, 1992.

62. Gronert GA, Theye RA, Milde JH, et al: Catecholamine stimulation of myocardial oxygen consumption in porcine malignant hyperthermia. Anesthesiology 49:330, 1978.

63. Roewer N, Dziadzka A, Greim CA, et al: Cardiovascular and metabolic responses to anesthetic-induced malignant hyperthermia in swine. Anesthesiology 83:141, 1995.

64. Cabral R, Prior PF, Scott DF, et al: Reversible profound depression of cerebral electrical activity in hyperthermia. Electroencephalogr Clin Neurophysiol 42:697, 1977.

65. Satnick JH: Hyperthermia under anesthesia with regional muscle flaccidity. Anesthesiology 30:472, 1969.

66. Artru AA, Gronert GA: Cerebral metabolism during porcine malignant hyperthermia. Anesthesiology 53:121, 1980.

67. Kochs E, Hoffman WE, am Esch JS: Improvement of brain electrical activity during treatment of porcine malignant hyperthermia with dantrolene. Br J Anaesth 71:881, 1993.

68. Hofer RE, Wedel DJ, Sharbrough FW: The effects of malignant hyperthermia on cerebral metabolites and the electroencephalogram in Pietrain swine. Anesthesiology 79:A435, 1993.

69. Gronert GA, Milde JH, Theye RA: Role of sympathetic activity in porcine malignant hyperthermia. Anesthesiology 47:411, 1977.

70. Gronert GA, White DA: Failure of norepinephrine to initiate porcine malignant hyperthermia. Pflugers Arch 411:226, 1988.

71. Maccani RM, Wedel DJ, Hofer RE: Norepinephrine does not potentiate porcine malignant hyperthermia. Anesth Analg 82:790, 1996.

72. Gronert GA, Milde JH, Taylor SR: Porcine muscle responses to carbachol, α- and β-adrenoceptor agaonists, halothane or hyperthermia. J Physiol (Lond) 307:319, 1980.

73. Lister D, Hall GM, Lucke JN: Porcine malignant hyperthermia. III. Adrenergic blockade. Br J Anaesth 48:831, 1976.

74. Cooper P, Meddings JB: Erythrocyte membrane fluidity in malignant hyperthermia. Biochim Biophys Acta 1069:151, 1991.

75. Sei Y, Gallagher KL, Basile AS: Skeletal muscle type ryanodine receptor is involved in calcium signaling in human B lymphocytes. J Biol Chem 274:5995, 1999.

76. Girard T, Cavagna D, Padovan E, et al: B-lymphocytes from malignant hyperthermia susceptible patients have an increased sensitivity to skeletal muscle ryanodine receptor activators. J Biol Chem 276:48077, 2001.

77. Carr RJ, Belani KG, Iaizzo PA, et al: Porcine malignant hyperthermia and liver transplantation: Further insight into systemic pathophysiology. Anesth Analg 80:S68, 1995.

78. Antognini JF: Creatine kinase alterations after acute malignant hyperthermia episodes and common surgical procedures. Anesth Analg 81:1039, 1995.

79. Nishiyama K, Kitahara A, Natsume H, et al: Malignant hyperthermia in a patient with Graves' disease during subtotal thyroidectomy. Endocr J 48:227, 2001.

80. Wappler F, Roewer N, Kochling A, et al: Fulminant malignant hyperthermia associated with ketoacidotic coma. Intensive Care Med 22:809, 1996.

81. Behnia R: Systemic effects of absolute alcohol embolization in a patient with a congenital arteriovenous malformation of the lower extremity. Anesth Analg 80:415, 1995.

82. Kitanaka C, Inoh Y, Toyoda T, et al: Malignant brain stem hyperthermia caused by brain stem hemorrhage. Stroke 25:518, 1994.

83. Lambert C, Blanloeil Y, Krivosic-Horber R, et al: Malignant hyperthermia in a patient with hypokalemic periodic paralysis. Anesth Analg 79:1012, 1994.

84. Gronert GA, Fowler W, Cardinet GH III, et al: Absence of malignant hyperthermia contractures in Becker-Duchenne dystrophy at age 2. Muscle Nerve 15:52, 1992.

85. Butler-Browne GS, Eriksson P-O, Laurent C, et al: Adult human masseter muscle fibers express myosin isozymes characteristic of development. Muscle Nerve 11:610, 1988.

86. Morgan DL, Proske U: Vertebrate slow muscle: Its structure, pattern of innervation, and mechanical properties. Physiol Rev 64:103, 1984.

87. van der Spek AFL, Reynolds PI, Fang WB, et al: Changes in resistance to mouth opening induced by depolarizing and non-depolarizing neuromuscular relaxants. Br J Anaesth 64:21, 1990.

88. Albrecht A, Wedel DJ, Gronert GA: Masseter muscle rigidity and non-depolarizing neuromuscular blocking agents. Mayo Clin Proc 72:329, 1997.

89. Martyn JAJ, White DA, Gronert GA, et al: Up-and-down regulation of skeletal muscle acetylcholine receptors: Effects on neuromuscular blockers. Anesthesiology 76:822, 1992.

90. Larach MG, Rosenberg H, Gronert GA, et al: Hyperkalemic cardiac arrest during anesthesia in infants and children with occult myopathy. Clin Pediatr (Phila) 36:9, 1997.

91. Schulte-Sasse U, Eberlein HJ, Schmucker I: Sollte die Verwendung von Succinylcholin in der Kinderanästhesie neu überdacht werden? Anaesthol Reanimat 18:13, 1993.

92. Gronert GA: Cardiac arrest after succinylcholine: Mortality greater with rhabdomyolysis than receptor upregulation. Anesthesiology 94:523, 2001.

93. Lee G, Antognini JF, Gronert GA: Complete recovery after prolonged resuscitation and cardiopulmonary bypass for hyperkalemic cardiac arrest. Anesth Analg 79:172, 1994.

94. Brustowicz RM, Moncorge C, Koka BV: Metabolic responses to tourniquet release in children. Anesthesiology 67:792, 1987.

95. Allen GC, Brubaker CL: Human malignant hyperthermia associated with desflurane anesthesia: The onset of MH. Anesth Analg 86:1328, 1998.

1189

96. Shulman M, Braverman B, Ivankovich AD, Gronert GA: Sevoflurane triggers malignant hyperthermia in swine. Anesthesiology 54:259, 1981.

97. Hall GM, Lucke JN, Lister D: Porcine malignant hyperthermia. IV. Neuromuscular blockade. Br J Anaesth 48:1135, 1976.

98. Iaizzo PA, Kehler CH, Carr RJ, et al: Prior hypothermia attenuates malignant hyperthermia in susceptible swine. Anesth Analg 82:803, 1996.

99. Gronert GA: Hyperbaric nitrous oxide and malignant hyperpyrexia. Br J Anaesth 53:1238, 1981.

100. McIntyre AR, King RE, Dunn AI: Electrical activity of denervated mammalian skeletal muscle as influenced by D-tubocurarine. J Neurophysiol 8:297, 1945.

101. Lips FJ, Newland M, Dutton G: Malignant hyperthermia triggered by cyclopropane during cesarean section. Anesthesiology 56:144, 1982.

102. Sewall K, Flowerdew RMM, Bromberger P: Severe muscular rigidity at birth: Malignant hyperthermia syndrome? Can Anaesth Soc J 27:279, 1980.

103. Cannon ML, Glazier SS, Bauman LA: Metabolic acidosis, rhabdomyolysis, and cardiovascular collapse after prolonged propofol infusion. J Neurosurg 95:1053, 2001.

104. Kelly DF: Editorial: Propofol-infusion syndrome. J Neurosurg 95:925, 2001.

105. Fruen BR, Mickelson JR, Roghair TJ, et al: Effects of propofol on Ca²⁺ regulation by malignant hyperthermia-susceptible muscle membranes. Anesthesiology 82:1274, 1995.

106. Wappler F, Fiege M, Antz M, et al: Hemodynamic and metabolic alterations in response to graded exercise in a patient susceptible to malignant hyperthermia. Anesthesiology 92:268, 2000.

107. Wappler F, Fiege M, Steinfath M, et al: Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis. Anesthesiology 94:95, 2001.

108. Davis M, Brown R, Dickson A, et al: Malignant hyperthermia associated with exercise-induced rhabdomyolysis or congenital abnormalities and a novel RYR1 mutation in New Zealand and Australian pedigrees. Br J Anaesth 88:508, 2002.

109. Tobin JR, Jason DR, Nelson TE, et al: Malignant hyperthermia and apparent heat stroke (Correspondence). JAMA 286:168, 2001.

110. Ogletree JW, Antognini JF, Gronert GA: Postexercise muscle cramping associated with positive malignant hyperthermia contracture testing. Am J Sports Med 24:49, 1996.

111. Ryan JF, Tedeschi LG: Sudden unexplained death in a patient with a family history of malignant hyperthermia. J Clin Anesth 9:66, 1997.

112. Anetseder M, Hartung E, Klepper S, et al: Gasoline vapors induce severe rhabdomyolysis. Neurology 44:2393, 1994.

113. Denborough MA, Hopkinson KC, Banney DG: Firefighting and malignant hyperthermia. Br Med J 296:1442, 1988.

114. Karan SM, Crowl F, Muldoon SM: Malignant hyperthermia masked by capnographic monitoring. Anesth Analg 78:590, 1994.

115. Larach MG, Localio AR, Allen GC, et al: A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 80:771, 1994.

116. Caroff SN, Rosenberg H, Mann SC: Neuroleptic malignant syndrome in the critical care unit. Crit Care Med 30:2609, 2002.

117. Reijneveld JC, Notermans NC, Linssen WHJP, et al: Benign prognosis in idiopathic hyper-CK-emia. Muscle Nerve 23:575, 2000.

118. Haji-Michael PG, Hatch DL: Smith-Lemli-Opitz syndrome and malignant hyperthermia. Anesth Analg 83:200, 1996.

119. Ducart A, Adnet P, Renaud B, et al: Malignant hyperthermia during sevoflurane anesthesia. Anesth Analg 80:609, 1995.

120. Mitchell LW, Leighton BL: Warmed diluent speeds dantrolene reconstitution. Can J Anaesth 50:127, 2003.

121. Lerman J, McLeod ME, Strong HA: Pharmacokinetics of intravenous dantrolene in children. Anesthesiology 70:625, 1989.

122. Flewellen EH, Nelson TE, Jones WP, et al: Dantrolene dose response in awake man: Implications for management of malignant hyperthermia. Anesthesiology 59:275, 1983.

123. Brandom BW, Larach MG, North American MH Registry: Reassessment of the safety and efficacy of dantrolene. Anesthesiology 97:A1199, 2002.

124. Gronert GA, Ahern CP, Milde JH: Treatment of porcine malignant hyperthermia: Lactate gradient from muscle to blood. Can J Anaesth 33:729, 1986.

125. Shime J, Gare D, Andrews J, et al: Dantrolene in pregnancy: Lack of adverse effects on the fetus and newborn infant. Am J Obstet Gynecol 159:831, 1988.

126. Schönell LHB, Sims C, Bulsara M: Preparing a new generation anaesthetic machine for patients susceptible to malignant hyperthermia. Anaesth Intens Care 31:58, 2003.

127. Roberts MC, Mickelson JR, Patterson EE, et al: Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1). Anesthesiology 95:716, 2001.

128. Cosgrove SB, Eisele PH, Martucci RW, et al: Evaluation of Greyhound susceptibility to malignant hyperthermia using halothane-succinylcholine anesthesia and caffeine-halothane contractures. Lab Anim Sci 42:482, 1992.

129. Antognini JF, Eisele PH, Gronert GA: Evaluation for malignant hyperthermia susceptibility in black-tailed deer. J Wildlife Dis 32:678, 1996.

130. Wappler F, Anetseder M, Baur CP, et al: Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility. European J Anaesth 20:528, 2003.

131. Antognini JF, Gronert GA: Effect of temperature variation (22C-44C) on halothane and caffeine contracture testing in humans. Acta Anaesthesiol Scand 41:639, 1997.

132. Ording H, Brancadoro V, Cozzolino S, et al: In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH group: Results of testing patients surviving fulminant MH and unrelated low-risk subjects. Acta Anaesthesiol Scand 41:955, 1997.

133. Allen GC, Larach MH, Kunselman AR: The sensitivity and specificity of the caffeine halothane contracture test: A report from the North American malignant hyperthermia registry. Anesthesiology 88:579, 1998.

134. Islander G, Ording H, Bendixen D, et al: Reproducibility of in vitro contracture test results in patients tested for malignant hyperthermia susceptibility. Acta Anaesth Scand 46:1144, 2002.

135. Robinson RL, Anetseder MJ, Brancadoro V, et al: Recent advances in the diagnosis of malignant hyperthermia susceptibility: How confident can we be of genetic testing? European J Human Genet 11:342, 2003.

136. Anetseder M, Hager M, Müller CR, et al: Diagnosis of susceptibility to malignant hyperthermia by use of a metabolic test. Lancet 359:1579–1580, 2002; 362:494, 2003.

137. Anetseder M, Hager M, Müller R, et al: Provocative metabolic testing for malignant hyperthermia by intramuscular caffeine and halothane application in humans. Anesthesiology 97:A432, 2002.

138. Kraev N, Loke JCP, Kraev A, et al: Protocol for the sequence analysis of ryanodine receptor subtype 1 gene transcripts from human leukocytes. Anesthesiology 99:289, 2003.

139. Loke JCP, Kraev N, Sharma P, et al: Detection of a novel ryanodine receptor subtype 1 mutation (R328W) in a malignant hyperthermia family by sequencing of a leukocyte transcript. Anesthesiology 99:297, 2003.

140. Bendahan D, Kozak-Ribbens G, Confort-Gouny S, et al: Definition of a diagnostic score of malignant hyperthermia using P-31 magnetic resonance spectroscopy [in French]. Ann Fr Anesth Reanim 15:583, 1996.

141. Antognini JF, Anderson M, Cronan M, et al: Ultrasonography: Not useful in detecting susceptibility to malignant hyperthermia. J Ultrasound Med 13:371, 1994.

1190

142. Adnet PJ, Reyford H, Tavernier BM, et al: In vitro human masseter muscle hypersensitivity: A possible explanation for increase in muscle tone. J Appl Physiol 80:1547, 1996.

143. Melton AT, Antognini JF, Gronert GA: Caffeine- or halothane-induced contractures of masseter muscle are similar to those of vastus muscle in normal humans. Acta Anaesth Scand 43:764, 1999.

144. Mozley PD: Malignant hyperthermia following intravenous iodinated contrast media. Diagn Gynecol Obstet 3:81, 1981.

145. Purday JP, Montgomery CJ, Blackstock D: Intraoperative hyperthermia in a paediatric patient with cystinosis. Paediatr Anaesth 5:389, 1995.

146. Scully RE (ed): Case records of the Mass. General Hospital. N Engl J Med 331:259, 1994.

147. Peluso A, Cerullo M: Malignant hyperthermia susceptibility in patients with osteogenesis imperfecta. Paediatr Anaesth 5:398, 1995.

148. Allen GC, Rosenberg H: Phaeochromocytoma presenting as acute malignant hyperthermia: A diagnostic challenge. Can J Anaesth 37:595, 1990.

149. Arkura K, Narita M, Nisimura C, et al: Malignant hyperthermia in a child with Prader-Willi syndrome. Anesth Resuscitation 32(Suppl):53, 1996.

150. Ginsburg R, Purcell-Jones GMH: Malignant hyperthermia in the Wolf-Hirschhorn syndrome. Anaesthesia 43:386, 1988.

151. Jones R, Dolcourt J: Muscle rigidity following halothane anesthesia in two patients with Freeman-Sheldon syndrome. Anesthesiology 77:599, 1992.